close
This ad will auto close in 10 seconds

Sun Pharma looking to divest Ireland plant

"Decisions are being made to either close or divest some of our manufacturing facilities," a Sun Pharma spokesman said in an emailed statement.

FDA hikes fee for drug approvals, cuts unit inspection charge

However, the fees for facility inspection of foreign companies have been reduced, which may encourage more firms to opt for audit of their facilities by the regulator.

Aurobindo Pharma CEO Arvind Vasudeva resigns

Recently, the drug firm had said that it intends to invest up to Rs 900 crore this fiscal on various activities including capacity expansion, clinical trials and product filings.

Glenmark to pay $24.96 mn to US to settle pricing probe

In a regulatory filing with the National Stock Exchange, the company said that under the terms of the agreed settlement, "there is no admission of liability".

Mankind Pharma setting up Rs 100 cr facility in Rajasthan

Mankind Pharma is investing around Rs 100 crore to set up an active pharmaceutical ingredients (API) facility in Rajasthan, which is expected to go on stream by the end of the year.

Lupin to acquire additional 40% stake in SA's Pharma Dynamics

Lupin had earlier acquired 60 per cent stake in the South African (SA) firm in September, 2008.

Ranbaxy loses approvals, exclusivity of 2 drugs in US

The DC Federal Court in the US has upheld the decision of the USFDA for rescinding tentative approvals given to it for generic digestive disorder drug Nexium and antiviral Valcyte.

Sun Pharma to buy GSK's opiates business in Australia

The business includes two manufacturing sites in Tasmania and Victoria, and consists of poppy-derived opiate raw materials mainly used to make analgesics for pain treatment. 

Lupin gets USFDA nod for ophthalmic solution

The company said it has received the final approval for its product, a generic version of Allergan Inc's Lumigan Ophthalmic Solution, from the US Food and Drug Administration (USFDA).

Glenmark bullish on drug discovery pipeline, eyes partnerships

Pain, inflammation and oncology are the therapeutic areas currently the drug maker is working on, said Glenn Saldanha, Chairman & Managing Director, Glenmark Pharmaceuticals Ltd.

Cipla forms JV in Morocco to enhance position in African market

Cipla (EU) Ltd, UK, a wholly-owned subsidiary of Mumbai-based drug firm, has inked the JV agreement with the Moroccan entities.

Ranbaxy Q3 net loss widens to Rs 1,029.72 cr

Ranbaxy Q3 net loss widens to Rs 1,029.72 cr

The company had posted a net loss of Rs 158.94 crore during the October-December period of previous fiscal.

German ban on Ranbaxy's Dewas product expands to entire EU

The company said it has discontinued manufacturing of an injectable antibiotic at its Dewas plant.

Sterilisation tragedy: Pharma company director, son remanded to judicial custody

The director of a pharmaceutical company and his son, which allegedly supplied "poor quality" medicines administered to victims of sterilisation surgeries in Chhattisgarh's Bilaspur district, were remanded to judicial custody today by a local court till December 2.

Sanofi sacks CEO over management row, shares plunge

French drugmaker Sanofi fired its chief executive on Wednesday after a row over his management style, sending the pharmaceutical giant`s shares sharply lower.

Benefit of Ranbaxy deal to accrue in few years: Sun Pharma

It will take a "few years" for Sun Pharma to realise the benefits of its USD 4 billion takeover of Ranbaxy, said the company's Chairman Israel Makov.

Wockhardt drug discovery gets fast track approval by USFDA

This is the first instance of an Indian pharmaceutical company receiving a QIDP status, Wockhardt said in a release issued here.

Cipla to invest upto 100 mn pounds in UK

The company will provide high quality affordable medicines to British National Health Service (NHS).

Lupin to set up two new R&D centres in US

The company had also increased research and development spending to Rs 958.28 crore in FY'14 as compared to Rs 770.85 crore in the FY'13.

Cipla Q4 Net Profit at Rs 260.69 cr

The company had posted a net profit of Rs 276.49 crore for the corresponding period of the previous fiscal.